What is ENGAGe?
The European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) is the ESGO network of European patient advocacy groups. It represents all gynaecological cancers (particularly ovarian, endometrial, cervical, vulvar, and rare cancers).
ENGAGe VISION and MISSION
- ENGAGe VISION
Prevention of gynaecological cancers and access to the best treatment.
- ENGAGe MISSION
To empower a patient-centric approach to gynaecological cancer care, research and prevention through awareness, advocacy and education.
Why is ENGAGe needed?
- There are wide variations in patient care across Europe
- Patients are not adequately informed about gynaecological cancer and their management
- Survivorship issues are not adequately addressed and psychosocial support in general is poor
The ENGAGe objectives are to:
- Facilitate the development of national gynaecological cancer patient groups in Europe and to facilitate networking and collaboration between them.
- Disseminate information and share best practices to empower patient groups and improve the quality of care across Europe.
- To increase patient representation in ESGO activities by education on current research and health policy.
- To advocate patient care policies practices and access to appropriate care at both national and European levels.
- To educate patient groups, health professionals, the public and health decision makers.
- Health Practitioners
- Women's health networks
- Patient Groups
- Cancer Organisations
- multidisciplinary input to treatment plans
- centralisation of specialist care
- individualization of treatment
- community care in local environment
- survivorship (>1 year)
Active areas of research
- Early diagnosis – primary care/community
- Targeted therapy
- Familial risk
- Selection of subgroups likely to benefit from individualized treatment
- Quality of Life
Why ESGO is the natural partner of patient networks
- The size of membership and meeting attendance reflect its global influence to ensure the gynaecological cancer patient perspective becomes integrated in the European cancer voice.
- Raise attention to the need for further research and improve access to quality treatment and care.
- No vested interests other than patient health makes it ideally placed to influence governments.
- Provides a comprehensive approach to the health of women with gynaecological cancer.
- Prospect of private/public partnership funding e.g. FP7, Horizon 2020.